Prognostic factors in patients with bone metastasis of renal cell carcinoma in the era of immune checkpoint inhibitors
Journal of Orthopaedic Science · 2026
DOI: 10.1016/j.jos.2025.06.008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Orthopaedic Science, 2026. Verfasst von Yuki Ishibashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: The University of Tokyo, Department of Orthopaedic Surgery, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Bone Neoplasms, Kidney Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Patients with clear cell renal cell carcinoma (ccRCC) have a higher incidence of bone metastasis; however, the availability of immune checkpoint inhibitors (ICIs) is expected to improve their overall survival (OS). Hence, accurate data on the prognosis and survival of patients with bone metastases are necessary to recommend appropriate treatments. Therefore, we investigated the prognosis and prognostic factors of patients with ccRCC bone metastasis in the era of ICIs. METHODS: This retrospective cohort study included 33 patients with ccRCC who were treated for bone metastases between 2016 and 2022. We evaluated the association between OS and clinical parameters, including serum biochemical concentrations, and blood cell count, using Kaplan-Meier curves and Cox proportional hazards models. RESULTS: The median OS was 28 months (95 % confidence interval (CI): 8 months - not censored), and the 1-year survival rate was 64 %. Twenty-one patients were treated with ICIs after bone metastasis diagnosis. The multivariate analysis revealed that the use of ICIs after bone metastasis diagnosis was a good prognostic factor (hazard ratio, 0.32; 95 % CI: 0.11-0.89, p = 0.029). Patients in the Katagiri score 5-7 points group using ICIs had a significantly longer survival (p = 0.012) but similar OS compared to the 2-4 points group (p = 0.34). CONCLUSIONS: ICI use after the diagnosis of bone metastasis may be a favorable prognostic factor in patients with bone metastases due to ccRCC. The predictive power of the current scoring system could underestimate the prognoses in patients with ccRCC and bone metastasis not treated with ICIs, highlighting the need for a better predictive scoring system in the era of ICIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The University of Tokyo, Department of Orthopaedic Surgery, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
- The University of Tokyo, Department of Orthopaedic Surgery, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. Electronic address: hkobayashi-tky@umin.ac.jp.
- Saitama Medical University, Department of Rehabilitation, 38 Morohongo Moroyama-machi, Iruma-gun, Saitama 350-0495, Japan.
- Kobe University, Department of Orthopaedic Surgery, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe City, Hyogo, 650-0017, Japan.
Zitieren
APA
Ishibashi, Y., Kobayashi, H., Okajima, K., Oki, T., Tsuda, Y., Shinoda, Y., Sawada, R., & Tanaka, S. (2026). Prognostic factors in patients with bone metastasis of renal cell carcinoma in the era of immune checkpoint inhibitors. Journal of Orthopaedic Science. https://doi.org/10.1016/j.jos.2025.06.008
Vancouver
Ishibashi Y, Kobayashi H, Okajima K, Oki T, Tsuda Y, Shinoda Y, et al. Prognostic factors in patients with bone metastasis of renal cell carcinoma in the era of immune checkpoint inhibitors. Journal of Orthopaedic Science. 2026. doi:10.1016/j.jos.2025.06.008
BibTeX
@article{Ishibashi2026,
author = {Ishibashi, Yuki and Kobayashi, Hiroshi and Okajima, Koichi and Oki, Takahiro and Tsuda, Yusuke and Shinoda, Yusuke and Sawada, Ryoko and Tanaka, Sakae},
title = {Prognostic factors in patients with bone metastasis of renal cell carcinoma in the era of immune checkpoint inhibitors},
journal = {Journal of Orthopaedic Science},
year = {2026},
doi = {10.1016/j.jos.2025.06.008}
}
EUVIMED